The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience

Albertson, Timothy E; Richards, John R.; Zeki, Amir A.

doi:10.1177/1753465815619136

Cited by 5 publications

(5 citation statements)

References 69 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current data suggest that FF/VI at doses of 100/25 µg or 200/25 µg can improve the lung function and quality of asthma control in patients with moderate to severe asthma as compared with ICS monotherapy [67,68]. One study compared FF/VI with the currently available FP/SAL BD combination inhaler, and there did not appear to be a significant difference in lung function, asthma control or side effects [64].…”

Section: Therapeutic Efficacymentioning

confidence: 98%

See 1 more Smart Citation

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Chang

Gray

Thomas

2016

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

FF has a highly specific, fast association and slow dissociation from the glucocorticoid receptor, with a 24 hr duration of action. This, combined with a slow transport out of respiratory cells, creates a long tissue retention period. Vilanterol trifenate (VI) is a new inhaled, selective, long - acting β2 adrenergic agonist, also with a rapid onset of action with a maximal effect within 6 mins and prolonged lung retention with effects on lung function over 24 hours. Expert commentary: Multiple Phase I-III efficacy studies performed on FF and VI have shown an improvement in spirometry as well as symptom control in asthma. The development of once daily ICS/LABA combinations may potentially improve adherence to asthma therapy, but this has yet to be demonstrated.

show abstract

Section: Therapeutic Efficacymentioning

confidence: 98%

“…One study compared FF/VI with the currently available FP/SAL BD combination inhaler, and there did not appear to be a significant difference in lung function, asthma control or side effects [64]. FF/VI is as efficacious with current asthma regimens, with the added benefit of it being a once-daily dosed inhaler [67,68].…”

Section: Therapeutic Efficacymentioning

confidence: 99%

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Chang

Gray

Thomas

2016

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Он характеризуется более высокой, чем формотерол и индакатерол, уровнем селективности к β 2 -адренорецепторам, что обеспечивает увеличение продолжительности действия на β 2 -рецептор, более низкую системную экспозицию и благоприятный профиль безопасности. Действие препарата начинается через 5,8 мин после ингаляции и длится 24 ч, что обеспечивает так называемый ультрадлительный бронхолитический эффект [20]. Основные клинические исследования с использованием ингаляционного вилантерола при БА представлены в табл.…”

Section: комбинация игкс с ддба -основа терапии бронхиальной астмыunclassified

Bronchial asthma: focus on adherence to inhaled therapy

Fesenko

2022

Medicinskij sovet

View full text Add to dashboard Cite

The rising incidence of the disease, severe exacerbations, and risks of death make bronchial asthma an urgent public health problem. Effective control of the disease is recognised as the main goal of modern therapy. Studies conducted in our country and abroad show a low level of bronchial asthma control in most patients. An important condition for achieving control is the patient’s adherence to therapy. Higher adherence rates and, consequently, improved quality of life have been recorded in patients receiving baseline therapy, which involves a single inhalation per day. The long-acting combination powder inhaler fluticasone furoate/ vilanterol is one of the modern drugs with proven efficacy and safety. The drug has been shown to significantly improve lung function and reduce the frequency of asthma exacerbations. Of particular note are the results of a randomised clinical trial carried out in real (everyday) clinical practice. This form of study is non-selective, i.e. it includes a wide group of patients regardless of severity, comorbidities and lifestyle. This approach was used in a study called the Salford Lung Study. It included patients with bronchial asthma who were receiving ongoing maintenance therapy with inhaled glucocorticosteroids or combinations thereof from primary care centres. The study lasted for 52 weeks. The first group consisted of patients treated with the fluticasone furoate/vilanterol combination. Group 2 patients continued to receive baseline therapy. The best response was observed with the fluticasone furoate/vilanterol combination. It was maintained in all subgroups analyzed and was independent of smoking status, baseline control reduction, and number of severe exacerbations in the past year. Adherence to treatment is improved by a single dose and a convenient, intuitive means of delivery. The inhaler requires minimal coordination, is activated with a single movement and has an easy-to-understand dose counter.

show abstract

“…It is approved for the treatment of asthma in England, Europe, and Japan under the trade name of Relvar® Ellipta®, and in the United States as Breo® Ellipta. 29 – 31 Extensive reviews have summarized data from multiple RCTs supporting the use of inhaled dry-powder FF/VI as a maintenance treatment in asthmatic patients not controlled on an ICS alone. 29 – 32 A detailed review of the multiple pharmacodynamic and pharmacokinetic assessments of inhaled FF/VI in the treatment of asthma is also available.…”

Section: Introduction and Limitations Of The Randomized Controlled Trmentioning

confidence: 99%

The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials

Albertson

Murin

Sutter

et al. 2017

POR

View full text Add to dashboard Cite

The Salford Lung Study (SLS) of patients with asthma and chronic obstructive pulmonary disease (COPD) is a practical, community-based, randomized, open-label pragmatic study on the efficacy and safety of the once-daily dry powder inhaler that combines the inhaled corticosteroid fluticasone furoate (FF) with the long-acting beta2 agonist vilanterol (VI). The asthma component of the SLS is not yet reported but the COPD component, done over a 12-month period, found a statistically significant 8.4% reduction in COPD exacerbations when compared to usual care. No differences in adverse events, including serious adverse events and pneumonia, were noted. The importance of real-world findings, such as those found in the SLS COPD trial with inhaled FF/VI, is discussed in comparison to classical randomized controlled trials (RCTs) with inhaled FF/VI in COPD patients. The real-world, community-based pragmatic RCT like the SLS provides additional generalizable data with direct clinical applicability and potential usefulness in the development of practice guidelines. The results from the SLS, along with those of large and small RCTs, are supportive of the use of once-daily FF/VI in COPD maintenance therapy.

show abstract

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience

Cited by 5 publications

References 69 publications

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

Bronchial asthma: focus on adherence to inhaled therapy

The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials

Contact Info

Product

Resources

About